EP Patent

EP4638743A2 — Small interfering rna targeting cfb and uses thereof

Assigned to Sanegene Bio USA Inc · Expires 2025-10-29 · 1y expired

What this patent protects

This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human CFB mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating CFB gene expression.

USPTO Abstract

This disclosure relates to isolated oligonucleotides comprising duplex regions targeting human CFB mRNA, and delivery systems, kits and compositions comprising the same, and methods of using the same for inhibiting or downregulating CFB gene expression.

Drugs covered by this patent

Patent Metadata

Patent number
EP4638743A2
Jurisdiction
EP
Classification
—
Expires
2025-10-29
Drug substance claim
No
Drug product claim
No
Assignee
Sanegene Bio USA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.